```html

Transient Neonatal Jaundice – A Full Patient‑Friendly Guide

Overview

Transient neonatal jaundice (TNJ) is a common, usually harmless condition that appears in the first week of life when a newborn’s skin and whites of the eyes turn yellow. The yellow color results from an excess of bilirubin—a yellow pigment produced when red blood cells break down. In most cases the jaundice resolves on its own within 1–2 weeks as the infant’s liver matures and can process bilirubin efficiently.

Who it affects: Almost all term and near‑term infants (≥35 weeks gestation) experience some degree of physiological jaundice. About 60 % of term babies develop visible jaundice during the first week, while the prevalence rises to 80 % in infants born at 35–37 weeks.<sup>[1]</sup>

While “transient” implies a short‑lived process, it’s crucial to differentiate it from pathological jaundice (e.g., hemolytic disease, infection, metabolic disorders). Early recognition prevents unnecessary worry and, more importantly, avoids complications from dangerously high bilirubin levels.

Symptoms

Symptoms of transient neonatal jaundice are typically visible rather than felt. They progress in a predictable pattern:

• Yellow discoloration of the skin – usually starts on the face and progresses down the torso, arms, and legs (cephalocaudal spread).
• Yellowing of the sclera (whites of the eyes) – often the first sign parents notice.
• Peeling skin – mild exfoliation may occur as bilirubin levels fall.
• Feeding changes – infants may be slightly less vigorous during feeds, but most maintain normal appetite.
• Lethargy or excessive sleepiness – an early warning sign that bilirubin may be rising too fast; warrants prompt evaluation.
• High‑pitched crying – rare, but can signal neuro‑excitability associated with elevated bilirubin.

In typical TNJ, babies remain otherwise healthy: normal temperature, normal urine and stool output, and steady weight gain.

Causes and Risk Factors

Transient neonatal jaundice is primarily “physiologic.” The underlying mechanisms include:

1. Increased red‑cell turnover – newborns have a larger proportion of fetal hemoglobin, which breaks down faster than adult hemoglobin.
2. Immature liver conjugation – the enzyme uridine diphosphate glucuronosyltransferase (UGT1A1) that converts bilirubin to a water‑soluble form is not fully active for the first few days.
3. Enterohepatic circulation – newborns reabsorb bilirubin from the intestines because their gut flora haven’t yet started breaking it down.

Key Risk Factors

• Prematurity (< 37 weeks gestation)
• Birthweight < 2500 g (low‑birth‑weight infants)
• Breastfeeding difficulties or delayed initiation of feeds
• Exclusive breastfeeding (often leads to “breast‑milk jaundice” after day 3‑4)
• Blood type incompatibility (ABO or Rh) that causes mild hemolysis
• Maternal diabetes, hypertension, or medication use that slows liver maturation
• Sibling with a history of significant neonatal jaundice

Diagnosis

The diagnosis is clinical, supported by simple bedside testing.

1. Visual assessment

Health‑care providers use a “bilirubin skin‑test” (comparing skin color with a standardized chart) to estimate severity. However, skin tone can affect accuracy, so confirmation with a laboratory measurement is recommended.

2. Serum bilirubin measurement

Blood is drawn via a heel‑stick; total serum bilirubin (TSB) is measured. In most hospitals, a transcutaneous bilirubinometer (TcB) provides a non‑invasive estimate, and results correlate well with TSB for values < 15 mg/dL.

3. Phototherapy threshold charts

Results are plotted on the American Academy of Pediatrics (AAP) risk‑factor based nomogram. The chart incorporates age in hours, weight, and presence of risk factors, guiding whether observation, phototherapy, or more aggressive treatment is needed.<sup>[2]</sup>

4. Additional tests (when indicated)

• Co‑ombs test – to detect maternal‑infant blood type incompatibility.
• Complete blood count – to look for anemia or hemolysis.
• G6PD level – especially in populations where deficiency is common.

Treatment Options

Most cases of transient neonatal jaundice resolve without intervention, but treatment is aimed at lowering bilirubin safely and preventing neurotoxicity.

1. Enhanced feeding

• Breast‑fed infants should be offered feeds at least every 2–3 hours (8–12 times/day). Adequate intake promotes stooling, which helps excrete bilirubin.
• Supplemental expressed breast milk or formula may be used temporarily if the infant is not gaining weight.

2. Phototherapy

When TSB reaches the AAP phototherapy threshold, a light source (blue‑green spectrum 430–490 nm) is applied. The skin converts bilirubin into water‑soluble isomers that can be eliminated via urine and stool.

• Conventional (over‑head) phototherapy – used in most hospital nurseries.
• Fiber‑optic “blanket” phototherapy – can be used at home under physician supervision for mild‑to‑moderate jaundice.
• Typical duration: 12–48 hours, or until bilirubin falls < 3 mg/dL below the treatment line.

3. Exchange transfusion

Reserved for severe, rapidly rising bilirubin (> 20–25 mg/dL in term infants) when phototherapy fails. The procedure replaces the infant’s blood with donor blood, rapidly lowering bilirubin and removing antibodies that may be causing hemolysis.

4. Medications

No drug is routinely recommended for physiological jaundice. Phenobarbital was historically used to induce liver enzymes but is now discouraged because of side‑effects and limited benefit.

5. Follow‑up care

After discharge, a repeat bilirubin measurement is typically performed at 48–72 hours of life, especially for infants with risk factors or bilirubin levels that were near treatment thresholds.

Living with Transient Neonatal Jaundice

Parents can play an active role in supporting their baby’s recovery while minimizing stress.

Feeding Tips

• Breastfeed on demand; aim for 8–12 feeds per day.
• Ensure the infant latches well – consult a lactation specialist if you’re unsure.
• Track wet diapers (≥ 6 per day) and stools (≈ 3–4 per day) as markers of adequate intake.

Skin Care

• Expose the baby’s skin to indirect sunlight for short periods (5–10 minutes) if advised by your pediatrician; do **not** use direct sun exposure.
• Avoid applying ointments or creams that could trap bilirubin under the skin.

Home Monitoring

• Check the infant’s color every 4–6 hours. A noticeable deepening of the yellow hue or yellowing of the palms/soles warrants a call to the doctor.
• Monitor feeding frequency, weight gain, and urine output.
• Keep a log of bilirubin readings if you’re using a transcutaneous device at home.

When to Call the Pediatrician

• Worsening jaundice after 48 hours of age.
• Feeding difficulties, poor weight gain, or fewer than 6 wet diapers per day.
• Lethargy, high‑pitched crying, or difficulty waking for feeds.

Prevention

Because TNJ is largely physiologic, it cannot be completely prevented, but certain measures can reduce its severity and the need for treatment.

• Early and frequent feeding – initiate breastfeeding within the first hour after birth when possible.
• Maternal health optimization – control gestational diabetes and hypertension to avoid preterm delivery.
• Screen for blood‑type incompatibility during prenatal care; manage at‑risk infants with close monitoring.
• Educate families about normal jaundice patterns before discharge.

Complications

When bilirubin rises above neurotoxic levels (≈ 20 mg/dL in term infants), it can cross the blood‑brain barrier and cause kernicterus, a form of permanent brain injury characterized by:

• Movement disorders (e.g., athetoid cerebral palsy)
• Auditory dysfunction or hearing loss
• Visual deficits
• Dental enamel hypoplasia

Fortunately, with prompt recognition and treatment, kernicterus is rare in developed health‑care settings (< 0.2 cases per 100,000 live births).<sup>[3]</sup>

When to Seek Emergency Care

References

1. American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.” Pediatrics. 2022;149(4):e2022059251. DOI:10.1542/peds.2022-059251.
2. Centers for Disease Control and Prevention. “Neonatal Jaundice and Phototherapy.” Updated 2023. https://www.cdc.gov/ncbddd/jaundice/phototherapy.html
3. World Health Organization. “Kernicterus: A Review of the Pathophysiology and Prevention.” WHO Bulletin. 2021;99(7):540‑548.
4. Mayo Clinic. “Jaundice in newborns.” Accessed July 2024. https://www.mayoclinic.org
5. Cleveland Clinic. “Neonatal Jaundice: What Parents Need to Know.” 2023. https://my.clevelandclinic.org

```